Abingworth — 2025 Investments
3 investments dated 2025 · listed companies and verified rows first · show all
Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).
BiotechHealthtechSouth San Francisco, US
Javier Szwarcberg(Executive Officer, Director)Samir Gharib(Executive Officer)RICHARD KING(Executive Officer, Director)
BoardSimpson Camilla(Director)Tiba Aynechi(Director)in
Board seatBali Muralidhar· per SEC Form D · $50M raise · filed Oct 2025
Co-investorsAisling CapitalHealthCapRiverVest Venture PartnersNorwest Venture PartnersOrbiMed
St. Louis, US
Board seatBali MuralidharNatalie Mount· per SEC Form D · $163M raise · filed Jul 2026
Addition Therapeutics develops genetic medicines using its all-RNA, non-viral, LNP-based PRINT platform, which combines the profile of RNA therapeutics with the durability of gene therapies.
BiotechHealthtechSouth San Francisco, US
Kathleen Collins(Director)Matthew Patterson(Director)Lawrence Kong(Executive Officer)Jennifer Lee(Director)Ronald Park(Executive Officer, Director)
BoardJayson Punwani(Director)
Co-investorsSR One Capital ManagementOsage University PartnersPivotal Life Sciences
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.